

Arlington Street, Boston, MA
02116-3912
February 14–February 15, 2000
Chicago Marriott O'Hare, 8535 West
Higgins Road, Chicago, IL 60631
February 16–February 17, 2000
Harvey Hotel Dallas-Fort Worth
Airport, 4545 John Carpenter
Parkway, Irving, TX 76039
February 24–25, 2000
Park Plaza International San
Francisco, 11177 Airport
Boulevard, Burlingame, CA 94010
February 28–February 29, 2000
Hilton Philadelphia Airport, 4509
Island Avenue, Philadelphia, PA
19153
April 5, 2000
AADS and IADR Meetings,
Washington Convention Center,
Washington, DC

No registration fee is required. The time for each workshop will be: (a) Day 1—7 p.m.–9 p.m., (b) Day 2—8:30 a.m.–3 p.m.

The objective of the Centers for Research to Reduce Oral Health Disparities (CRROHD) initiative is to reduce health disparities in children and their caregivers through basic, patient-oriented/clinical, translational and community research, through training and career development, and through community outreach/service.

The purposes of the workshops are to:

- Bring together potential applicants from the various and diverse communities including colleges/schools/departments of academic health institutions representing the entire spectrum of the health professions (*e.g.*, dentistry, medicine, nursing, pharmacy, veterinary sciences, behavioral and social sciences), state and local health and health financing agencies (*e.g.*, state Medicaid agencies and children's health insurance programs), community and migrant health centers, Indian health service clinics, CDC-sponsored Prevention Research Centers, minority and minority-serving institutions (*e.g.*, Historically Black Colleges and Universities; Hispanic-serving institutions, tribal colleges and universities), and other groups interested in this initiative; and

- Address questions relating to the development of applications in response to the Request for Applications (RFA DE-99-003) available through the NIDCR Health Disparities Home Page (http://www.nidcr.nih.gov/opportunities/health_disp.htm) or directly from the electronic version of the NIH Guide to Grants and Contracts (<http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-99-003.html>).

Representatives from various government agencies involved in this

RFA will be available to answer questions and provide additional guidance.

Participants are responsible for making arrangements for their own travel and overnight accommodations. Blocks of sleeping rooms have been set aside at each workshop site at a special rate for federal and nonfederal participants. For additional information please contact Ms. Lorraine Jackson on (301) 594-2616; email: Lorraine.Jackson@nih.gov or Dr. Norman S. Braveman (301) 594-2089; email: Norman.Braveman@nih.gov or visit the NIDCR Health Disparities Activities web site: (http://www.nidcr.nih.gov/opportunities/health_disp.htm).

Dated: December 21, 1999.

Yvonne H. du Buy,

Associate Director for Management, NIDCR.

[FR Doc. 00-61 Filed 1-3-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. (and in selected foreign markets) in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

ADDRESSES: Licensing information may be obtained by contacting Marlene Shinn at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; telephone: 301/496-7056 ext. 285; fax: 301/402-0220; e-mail: ms482m@nih.gov.

SUPPLEMENTARY INFORMATION: The NIH announces the issuance of U.S. Patent 5,958,778, entitled "Container for Drying Biological Samples, Method of Making Such Container, and Method of Using Same," developed by Dr. Geoffrey L. Kidd of the National Eye Institute.

Problem Addressed by This Invention

Many compounds, such as drugs, growth factors, etc., must be kept sterile and must be aliquotted for storage. Usually, these aliquots are best stored lyophilized. Yet, researchers have never had a way to keep aliquots sterile

through the lyophilization process. Consequently, each aliquot has had to be filter-sterilized when reconstituted for use. This process has the disadvantages of consuming excessive filters, syringes, sterile, receptacles, and time and results in serious loss of precious sample due to absorption by the filters (especially with small aliquots less than 1 ml). Alternatively, researchers have had to forgo lyophilization and store their solutions in the less-stable frozen form.

Solution Offered by This Invention

Sterile-lyophilization tubes having a 0.22 micron filter built into the cap. This unique feature allows a sterile solution to remain sterile throughout lyophilization, even after the vacuum is released and air reenters the tube. Thus, a starting solution is simply filter-sterilized while in a relatively large volume, using a single filter and therefore suffering minimal loss and consuming little time. It is then aliquotted into sterile-lyophilization tubes and lyophilized. The tubes can then be transferred directly to the freezer, if desired. The compound is reconstituted when needed, and may then be used immediately without further filtration.

Potential Applications of This Invention

All researchers worldwide who utilize sterile, labile compounds will have an interest in this product, including governmental, university, institutional, and drug company laboratories. Most notably in need are investigators involved in drug-testing, which is normally done either in cell cultures, laboratory animals, or humans, and which requires sterility of many aliquots of many drugs. Additionally, this product will have a large market relating to basic research utilizing microbial, plant, or animal cell or organ cultures, to which sterile compounds such as growth factors are commonly added. Research in drugs, growth factors, etc., is expanding ever more rapidly, and generally requires a cell culture system in which to study such compounds. Most of these compounds are quite expensive. Loss of potency during storage and loss of material during filtration are widespread problems which may be overcome with this invention. Therefore, there exists a tremendous need, and immense market for, this sterile-lyophilization vessel.

Stage of Development

Development is complete and invention has been successfully tested. Prototypes are available.

Dated: December 29, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 00-62 Filed 1-3-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; National Cancer Institute Sponsors an Open Forum on the 5 a Day for Better Health Program

The National Cancer Institute (NCI) will sponsor an open forum to hear public comment during an assessment of the Institute's 5 a Day for Better Health Program. Members of the assessment team will examine a number of areas, including the program's success in achieving its goal and objectives, its scientific base, and its achievements in nutrition-related research, communications, and coalition-building.

The purpose of the open forum is to enable individuals representing health, research, and professional organizations, as well as private citizens, to provide oral comment on the 5 a Day program. The forum will be held on January 13, 2000 from 1 to 2:30 p.m. at the Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, VA 22202. NCI staff and members of the team will attend.

To enable NCI representatives to hear the widest range of views, oral comments will be limited to five minutes in length. In addition, the NCI may need to set a limit of one speaker per organization depending on the number of speakers. In order to have a written record of all comments, the NCI will have transcription services available for those who cannot provide a typed copy of their comments on or before January 13. Prior to the oral comment period, the NCI will provide a brief overview of the evaluation plan for the Program.

Requests for time to make oral presentations at the January 13 meeting need to be made in writing by January 11, 2000 to the contact person listed below.

Attendance at the forum will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodation, should notify the Contact person listed below in advance of the meeting.

NCI encourages anyone who is unable to make an oral presentation to submit a written statement for the record. Written statement may be submitted to the contact below until January 25, 2000.

FOR FURTHER INFORMATION CONTACT:

Kevin Callahan, Deputy Directors, Office of Science Policy, Planning and Assessment, National Cancer Institute, National Institutes of Health, Bldg. 31, Room 11A03, Bethesda, MD 20892, voice: 301-402-7519, fax 301-435-3876, e-mail: kc9t2@nih.gov.

Dated: December 27, 1999.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy, National Institutes of Health.

[FR Doc. 00-67 Filed 1-3-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel.

Date: January 12, 2000.

Time: 9 am to 2 pm.

Agenda: To review and evaluate grant applications.

Place: 6120 Executive Blvd. Suite 350, Rockville, MD 20892.

Contact Person: Andrew P. Mariani, Chief, Scientific Review Branch, 6120 Executive Blvd., Suite 350, Rockville, MD 20892; 301/496-5561.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: December 27, 1999.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-64 Filed 1-3-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552(c)(4) and 552(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel.

Date: January 6, 2000.

Time: 2 pm to 5 pm.

Agenda: To review and evaluate grant applications.

Place: 6120 Executive Blvd. Suite 350, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Andrew P. Mariani, Chief, Scientific Review Branch, 6120 Executive Blvd., Suite 350, Rockville, MD 20892; 301/496-5561.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, (HHS)

Dated: December 27, 1999.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-65 Filed 1-3-00; 8:45 am]

BILLING CODE 4140-01-M